| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from SYRE graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from SYRE graph: uld any of our product candidates be … |
| JNJ |
Johnson & Johnson |
72%
|
uld any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from SYRE graph: uld any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize th… |
| SNYNF |
Sanofi |
72%
|
uld any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/… |
| AEGLEA-BIOTHERAPEUTICS-HOLDINGS-LLC |
AEGLEA-BIOTHERAPEUTICS-HOLDINGS-LLC |
62%
|
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| AEGLEA-BIOTHERAPEUTICS-INC |
AEGLEA-BIOTHERAPEUTICS-INC |
62%
|
ubjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by commu… |
| ASPEN-MERGER-SUB-I-INC |
ASPEN-MERGER-SUB-I-INC |
62%
|
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| COMPANY-SEQUOIA-MERGER-SUB-II-LLC |
COMPANY-SEQUOIA-MERGER-SUB-II-LLC |
62%
|
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| EQUINITI-TRUST-COMPANY-LLC |
EQUINITI-TRUST-COMPANY-LLC |
62%
|
ial materials, study monitoring and data analysis that could materially adversely impact our business, results of operations and overall financial performance in future periods. As of the filing date… |
| EU-CLINICAL-TRIALS-EXPERT-GROUP |
EU-CLINICAL-TRIALS-EXPERT-GROUP |
62%
|
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| LIMITED-LIABILITY-COMPANY |
LIMITED-LIABILITY-COMPANY |
62%
|
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| PRESENTATION-SPYRE-THERAPEUTICS-INC |
PRESENTATION-SPYRE-THERAPEUTICS-INC |
62%
|
ubjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by commu… |
| TRUST-COMPANY-LLC |
TRUST-COMPANY-LLC |
62%
|
ial materials, study monitoring and data analysis that could materially adversely impact our business, results of operations and overall financial performance in future periods. As of the filing date… |
